Identifying therapeutic biomarkers of zoledronic acid by metabolomics

• Main Authors: Xiang Li (Author), Zi-Yuan Wang (Author), Na Ren (Author), Zhan-Ying Wei (Author), Wei-Wei Hu (Author), Jie-Mei Gu (Author), Zhen-Lin Zhang (Author), Xiang-Tian Yu (Author), Chun Wang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Zoledronic acid (ZOL) is a potent antiresorptive agent that increases bone mineral density (BMD) and reduces fracture risk in postmenopausal osteoporosis (PMOP). The anti-osteoporotic effect of ZOL is determined by annual BMD measurement. In most cases, bone turnover markers function as early indica...